文献速递乳腺癌放疗

多中心前瞻性Ⅱ期大分割PMRT试验5年更新

5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-04-11

该多中心Ⅱ期试验纳入69例Ⅱ-Ⅲa期乳腺癌患者,术后胸壁及区域淋巴引流区接受3.33 Gy×11次大分割放疗,可选瘢痕加量4次。中位随访54个月,无3-4级非重建相关急慢性毒性,≥2级晚期毒性12%,5年局部失败自由率92%、总生存90%。

要点

  • 大分割PMRT(3.33 Gy×11次)5年无3-4级非重建相关毒性。
  • ≥2级晚期毒性12%,为持续>6个月的疼痛、疲乏和淋巴水肿。
  • 5年局部失败自由率92%,总生存90%,仅3例(4.6%)以胸壁或淋巴结为首发复发。

核心结论

  • 大分割PMRT安全有效,并发症率低且局部控制良好,毒性低于既往PMRT系列预期。

研究设计与样本

  • 多中心、前瞻性、Ⅱ期试验,69例Ⅱ-Ⅲa期乳腺癌患者入组,67例可分析。
  • 放疗方案为胸壁(或重建乳房)及区域淋巴引流区3.33 Gy/次×11次,瘢痕加量4次可选。
  • 主要终点为≥3级晚期非重建相关放疗毒性自由率,采用CTCAE v4.0评分。

主要发现

  • 中位随访54个月,无急性或晚期3-4级非重建相关毒性报告。
  • ≥2级晚期毒性率为12%,包括持续>6个月的2级疼痛、疲乏和淋巴水肿。
  • 仅3例女性(4.6%)以胸壁或淋巴结为首发复发部位。
  • 5年局部失败自由率(含远处复发后局部失败)为92%,5年总生存率为90%。

关键数值与推荐

  • 大分割方案:3.33 Gy/次×11次,可选瘢痕加量4次。
  • 主要终点:≥3级晚期非重建相关放疗毒性自由率。
  • 5年局部失败自由率92%,5年总生存率90%。

临床怎么用

  • 该方案可作为大分割PMRT的循证选择,但需注意试验为Ⅱ期单臂设计。
  • 该试验是Alliance A221505(RT CHARM)Ⅲ期随机试验的基础,后者正在入组。

局限性

  • Ⅱ期单臂设计,样本量67例可分析,随访中位54个月。
  • 原文未报告对照臂或随机比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypofractionation in the setting of postmastectomy radiation (PMRT) is not currently the standard of care in most countries. Here we present a 5-year update of our multi-institutional, phase 2 prospective trial evaluating a novel 15-day hypofractionated PMRT regimen. METHODS AND MATERIALS: Patients were enrolled to receive 3.33 Gy daily to the chest wall (or reconstructed breast) and regional lymphatics in 11 fractions with an optional 4-fraction mastectomy scar boost. The primary endpoint was freedom from grade 3 or higher late non-reconstruction-related radiation toxicities. Toxicities were scored using Common Terminology Criteria for Adverse Events v4.0. Secondary endpoints included local and locoregional recurrence rates, cosmesis, and reconstruction complications. RESULTS: After enrolling 69 patients with stage II-IIIa breast cancer, 67 women were eligible for analysis. At a median follow up of 54 months, there were no acute or late grade 3 and 4 nonreconstruction reported toxicities. The grade 2 or greater late toxicity rate was only 12% and comprised grade 2 pain, fatigue, and lymphedema that persisted beyond 6 months after completion of radiation therapy. Only 3 women (4.6%) experienced a chest wall or nodal recurrence as a first site of relapse. Freedom from local failure, including local failure after distant relapse, was 92% at 5 years, and the 5-year overall survival was 90%. CONCLUSIONS: This is the first prospective trial conducted in the United States to demonstrate the safe and effective use of hypofractionated PMRT. We have demonstrated a low complication rate while achieving excellent local control. Toxicity was better than anticipated based on previously published series of PMRT toxicities. Although our fractionation was novel, the radiobiological equivalent dose is similar to other hypofractionation schedules. This trial was the basis for the creation of Alliance A221505 (RT CHARM), which is currently accruing patients in a phase 3 randomized design.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Poppe MM, Yehia ZA, Baker C, et al. 5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32289474. doi:10.1016/j.ijrobp.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。